Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gazyva

- PMLiVE

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Final decision due by 18 October

- PMLiVE

FDA sets June decision date for Tecentriq monotherapy in NSCLC

Aims for the first-line setting where Merck's Keytruda dominates

- PMLiVE

Merck chases Roche with triple-negative breast cancer data for Keytruda

Data demonstrated a delay in disease progression or death

- PMLiVE

Double blow to amyloid drug hopes as Roche, Lilly trial fails

The two investigational candidates were unable to show benefit

Roche Basel Switzerland

Roche builds case for SMA drug risdiplam as FDA verdict nears

Outcome of FDA review due by 24 May

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

Roche Basel Switzerland

Roche files Tecentriq/Avastin combo in liver cancer

First treatment in over a decade to improve overall survival

- PMLiVE

EU grants conditional approval to Roche’s lymphoma drug Polivy

Drug demonstrated a 40% complete response rate in trial

Roche Basel Switzerland

Roche and Illumina partner on genomics for cancer diagnostics

Will leverage genomics system to match optimal cancer treatment

- PMLiVE

NICE knocks back Roche’s Tecentriq for small cell lung cancer

Insufficient evidence to approve use in SCLC on the NHS

Roche Basel Switzerland

Roche pays $1.15bn for Sarepta’s Duchenne gene therapy

Pens another gene therapy deal following takeover of Spark Therapeutics

Roche Basel Switzerland

Roche to close $4.3bn Spark deal after FTC clearance

Comes on the heels of CMA green light

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links